Do analysts recommend RGC or ABVX?

Abivax has a consensus price target of $148.54, suggesting a potential upside of 8.70%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abivax 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.81

Which has stronger valuation & earnings, RGC or ABVX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is RGC or ABVX more profitable?

Regencell Bioscience's return on equity of 0.00% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Abivax N/A -99.02% -70.26%

Does the media favor RGC or ABVX?

In the previous week, Abivax had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Abivax and 1 mentions for Regencell Bioscience. Abivax's average media sentiment score of 1.41 beat Regencell Bioscience's score of -0.35 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RGC or RDY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings and valuation, RGC or RDY?

Dr. Reddy's Laboratories has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Dr. Reddy's Laboratories $335.93B 0.03 $456M $0.58 21.78

Does the media refer more to RGC or RDY?

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 1 mentions for Regencell Bioscience. Dr. Reddy's Laboratories' average media sentiment score of 0.42 beat Regencell Bioscience's score of -0.35 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CYTK or RGC?

Cytokinetics presently has a consensus target price of $99.90, suggesting a potential upside of 24.59%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cytokinetics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 1 Sell rating(s) 2 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.91 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, CYTK or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Cytokinetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $105.82M 94.29 -$784.96M -$6.84 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is CYTK or RGC more profitable?

Regencell Bioscience has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Company Net Margins Return on Equity Return on Assets Cytokinetics -784.02% N/A -52.86% Regencell Bioscience N/A N/A N/A

Does the media prefer CYTK or RGC?

In the previous week, Cytokinetics had 12 more articles in the media than Regencell Bioscience. MarketBeat recorded 13 mentions for Cytokinetics and 1 mentions for Regencell Bioscience. Cytokinetics' average media sentiment score of 1.00 beat Regencell Bioscience's score of -0.35 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RGC or ARWR?

Arrowhead Pharmaceuticals has a consensus target price of $88.75, suggesting a potential upside of 19.45%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Arrowhead Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71

Which has better earnings & valuation, RGC or ARWR?

Arrowhead Pharmaceuticals has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Arrowhead Pharmaceuticals $622.01M 16.83 -$1.63M -$2.15 N/A

Do analysts prefer RGC or KRYS?

Krystal Biotech has a consensus price target of $360.67, indicating a potential upside of 1.64%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83

Which has stronger earnings & valuation, RGC or KRYS?

Krystal Biotech has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Krystal Biotech $389.13M 26.88 $204.83M $7.48 47.44

Does the media favor RGC or KRYS?

In the previous week, Krystal Biotech had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Krystal Biotech and 1 mentions for Regencell Bioscience. Krystal Biotech's average media sentiment score of 1.13 beat Regencell Bioscience's score of -0.35 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Regencell Bioscience (RGC) Competitors

$5.02 +0.24 (+5.02%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$4.99 -0.03 (-0.66%)

As of 07/17/2026 07:59 PM Eastern

Compare

RGC vs. ABVX, RDY, CYTK, ARWR, and KRYS

Should you buy Regencell Bioscience stock or one of its competitors? MarketBeat compares Regencell Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Regencell Bioscience include Abivax (ABVX), Dr. Reddy's Laboratories (RDY), Cytokinetics (CYTK), Arrowhead Pharmaceuticals (ARWR), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Regencell Bioscience compare to Abivax?

Regencell Bioscience (NASDAQ:RGC) and Abivax (NASDAQ:ABVX) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

In the previous week, Abivax had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Abivax and 1 mentions for Regencell Bioscience. Abivax's average media sentiment score of 1.41 beat Regencell Bioscience's score of -0.35 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Regencell Bioscience's return on equity of 0.00% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Abivax	N/A	-99.02%	-70.26%

Abivax has a consensus price target of $148.54, suggesting a potential upside of 8.70%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Regencell Bioscience has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market. Comparatively, Abivax has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Abivax beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Regencell Bioscience (NASDAQ:RGC) and Dr. Reddy's Laboratories (NYSE:RDY) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Regencell Bioscience has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Regencell Bioscience's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Regencell Bioscience pays an annual dividend of $0.88 per share and has a dividend yield of 17.5%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Dr. Reddy's Laboratories pays out 10.3% of its earnings in the form of a dividend.

Dr. Reddy's Laboratories has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Dr. Reddy's Laboratories	$335.93B	0.03	$456M	$0.58	21.78

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 1 mentions for Regencell Bioscience. Dr. Reddy's Laboratories' average media sentiment score of 0.42 beat Regencell Bioscience's score of -0.35 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Dr. Reddy's Laboratories beats Regencell Bioscience on 9 of the 12 factors compared between the two stocks.

How does Regencell Bioscience compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Regencell Bioscience (NASDAQ:RGC) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Cytokinetics presently has a consensus target price of $99.90, suggesting a potential upside of 24.59%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cytokinetics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cytokinetics had 12 more articles in the media than Regencell Bioscience. MarketBeat recorded 13 mentions for Cytokinetics and 1 mentions for Regencell Bioscience. Cytokinetics' average media sentiment score of 1.00 beat Regencell Bioscience's score of -0.35 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regencell Bioscience has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Regencell Bioscience	N/A	N/A	N/A

Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

Regencell Bioscience has lower revenue, but higher earnings than Cytokinetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	94.29	-$784.96M	-$6.84	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Summary

Cytokinetics beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Arrowhead Pharmaceuticals?

Regencell Bioscience (NASDAQ:RGC) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Arrowhead Pharmaceuticals has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Arrowhead Pharmaceuticals	$622.01M	16.83	-$1.63M	-$2.15	N/A

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Regencell Bioscience. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 1 mentions for Regencell Bioscience. Arrowhead Pharmaceuticals' average media sentiment score of 0.73 beat Regencell Bioscience's score of -0.35 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Regencell Bioscience's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Arrowhead Pharmaceuticals has a consensus target price of $88.75, suggesting a potential upside of 19.45%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Arrowhead Pharmaceuticals beats Regencell Bioscience on 10 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Krystal Biotech?

Regencell Bioscience (NASDAQ:RGC) and Krystal Biotech (NASDAQ:KRYS) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Krystal Biotech has a net margin of 53.92% compared to Regencell Bioscience's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Krystal Biotech	53.92%	19.25%	17.62%

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Regencell Bioscience has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Krystal Biotech	$389.13M	26.88	$204.83M	$7.48	47.44

In the previous week, Krystal Biotech had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 6 mentions for Krystal Biotech and 1 mentions for Regencell Bioscience. Krystal Biotech's average media sentiment score of 1.13 beat Regencell Bioscience's score of -0.35 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a consensus price target of $360.67, indicating a potential upside of 1.64%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Krystal Biotech beats Regencell Bioscience on 12 of the 13 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGC vs. The Competition

Export

Metric	Regencell Bioscience	Medicinal Chemicals Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.48B	$1.26B	$4.40B	$12.28B
Dividend Yield	N/A	N/A	37.90%	9.34%
P/E Ratio	N/A	N/A	23.70	23.92
Price / Sales	N/A	2.13	93.72	88.82
Price / Cash	N/A	0.27	164.16	60.41
Price / Book	502.00	251.02	12.18	6.18
Net Income	-$3.58M	-$1.41M	$121.47M	$332.29M
7 Day Performance	-14.63%	-6.61%	-1.12%	-2.05%
1 Month Performance	-58.20%	-34.67%	-2.65%	-2.18%
1 Year Performance	-65.38%	-65.38%	9.79%	17.67%

Regencell Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGC Regencell Bioscience	0.2402 of 5 stars	$5.02 +5.0%	N/A	-65.4%	$2.48B	N/A	N/A	10	Analyst Downgrade Gap Down
ABVX Abivax	2.3484 of 5 stars	$136.94 +1.5%	$148.54 +8.5%	+1,273.4%	$10.76B	N/A	N/A	61	Positive News
RDY Dr. Reddy's Laboratories	1.8954 of 5 stars	$12.78 -0.5%	N/A	-12.7%	$10.72B	$3.58B	22.03	27,527	Upcoming Earnings
CYTK Cytokinetics	3.2562 of 5 stars	$82.62 +0.8%	$99.90 +20.9%	+115.4%	$10.19B	$88.04M	N/A	250	News Coverage Positive News Insider Trade Options Volume
ARWR Arrowhead Pharmaceuticals	3.1053 of 5 stars	$71.82 -0.1%	$88.17 +22.8%	+343.3%	$10.13B	$829.45M	N/A	400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGC) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regencell Bioscience (RGC) Competitors

RGC vs. ABVX, RDY, CYTK, ARWR, and KRYS

How does Regencell Bioscience compare to Abivax?

Summary

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Summary

How does Regencell Bioscience compare to Cytokinetics?

Summary

How does Regencell Bioscience compare to Arrowhead Pharmaceuticals?

Summary

How does Regencell Bioscience compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regencell Bioscience (RGC) Competitors

RGC vs. ABVX, RDY, CYTK, ARWR, and KRYS

How does Regencell Bioscience compare to Abivax?

Does the media favor RGC or ABVX?

Which has stronger valuation & earnings, RGC or ABVX?

Is RGC or ABVX more profitable?

Do analysts recommend RGC or ABVX?

Which has more risk and volatility, RGC or ABVX?

Do insiders and institutionals hold more shares of RGC or ABVX?

Summary

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Which has more risk and volatility, RGC or RDY?

Is RGC or RDY more profitable?

Do insiders & institutionals believe in RGC or RDY?

Is RGC or RDY a better dividend stock?

Which has higher earnings and valuation, RGC or RDY?

Does the media refer more to RGC or RDY?

Do analysts prefer RGC or RDY?

Summary

How does Regencell Bioscience compare to Cytokinetics?

Do analysts prefer CYTK or RGC?

Do institutionals & insiders have more ownership in CYTK or RGC?

Does the media prefer CYTK or RGC?

Is CYTK or RGC more profitable?

Which has more risk and volatility, CYTK or RGC?

Which has higher earnings & valuation, CYTK or RGC?

Summary

How does Regencell Bioscience compare to Arrowhead Pharmaceuticals?

Which has better earnings & valuation, RGC or ARWR?

Do institutionals and insiders have more ownership in RGC or ARWR?

Does the media refer more to RGC or ARWR?

Which has more risk & volatility, RGC or ARWR?

Is RGC or ARWR more profitable?

Do analysts prefer RGC or ARWR?

Summary

How does Regencell Bioscience compare to Krystal Biotech?

Is RGC or KRYS more profitable?

Do institutionals & insiders believe in RGC or KRYS?

Which has more volatility & risk, RGC or KRYS?

Which has stronger earnings & valuation, RGC or KRYS?

Does the media favor RGC or KRYS?

Do analysts prefer RGC or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools